Nurix Therapeutics, Inc. (NRIX) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Nurix (NRIX) PT Lowered to $28 at Needham
January 29, 2025 7:59 AM ESTNeedham analyst Gil Blum lowered the price target on Nurix (NASDAQ: NRIX) to $28.00 (from $29.00) while maintaining a Buy rating.
The analyst comments "Financials and Model Updates. In 2024, Nurix received ~$13M in collaboration revenue from its partners including a $5M milestone... More
